Gupta E, Samal J, Maiwall R, Tevethia H, Grover M, Rani N, et al. Respiratory tract viral infections associated sepsis in patients with underlying liver disease: Viral sepsis an entity to look forward! Indian J Gastroenterol. 2024 Apr;43(2):475–84.
Prabhakar T, Prasad M, Kumar G, Kaushal K, Shenoy PS, Dubey S, et al. High prevalence of MAFLD in general population: A large cross-sectional study calls for concerted public health action. Aliment Pharmacol Ther. 2024 Apr;59(7):843–51.
Prasad M, Gupta S, Sarin SK. The Independent Association of Non-alcoholic Fatty Liver Disease With Incident Cardiovascular Disease: A GRADE Evaluation of the Evidence Through a Systematic Review and Meta-analysis. J Clin Exp Hepatol. 2024 Feb;14(1):101277.
Prasad M, Prabhakar T, Sarin SK. Editorial: The tsunami of steatotic liver disease in India, the Asia-Pacific region and the world-Authors’ reply. Aliment Pharmacol Ther. 2024 Apr;59(7):902–3.
Samal J, Prabhakar T, Prasad M, Rani N, Tarai B, Agarwal R, et al. Prevalence and Predictors for Respiratory Viral Infections among Liver Disease Patients. Euroasian J Hepatogastroenterol. 2023 Dec;13(2):108–14.
Tomar M, Sharma T, Prasad M. Social challenges experienced by Hepatitis B patients: A mixed method study. J Family Med Prim Care. 2023 Apr;12(4):748–55.
Global burden and strength of evidence for 88 risk factors in 204 countries and 811 subnational locations, 1990-2021: a systematic analysis for the Global Burden of Disease Study 2021. Lancet. 2024 May 18;403(10440):2162–203.
Global burden of 288 causes of death and life expectancy decomposition in 204 countries and territories and 811 subnational locations, 1990-2021: a systematic analysis for the Global Burden of Disease Study 2021. Lancet. 2024 May 18;403(10440):2100–32.
Global age-sex-specific mortality, life expectancy, and population estimates in 204 countries and territories and 811 subnational locations, 1950-2021, and the impact of the COVID-19 pandemic: a comprehensive demographic analysis for the Global Burden of Disease Study 2021. Lancet. 2024 May 18;403(10440):1989–2056.
Global incidence, prevalence, years lived with disability (YLDs), disability-adjusted life-years (DALYs), and healthy life expectancy (HALE) for 371 diseases and injuries in 204 countries and territories and 811 subnational locations, 1990-2021: a systematic analysis for the Global Burden of Disease Study 2021. Lancet. 2024 May 18;403(10440):2133–61.
Lazarus JV, Mark HE, Allen AM, Arab JP, Carrieri P, Noureddin M, et al. A global research priority agenda to advance public health responses to fatty liver disease. J Hepatol. 2023 Sep;79(3):618–34.
Mane A, Agarwal R, Bajpai M, Sane S, Vidhate P, Rakshit P, et al. Validation of dried blood spot for serological diagnosis of Hepatitis B and C: a multicentric study. Diagn Microbiol Infect Dis. 2024 Feb;108(2):116108.
Prasad M, Gupta S, Kashyap N, Kapil U. Diagnostic performance of non-invasive liver fibrosis risk scores in biopsy-proven non-alcoholic fatty liver disease patients in India. Indian J Gastroenterol. 2023 Apr;42(2):192–8.
Mensah GA, Fuster V, Murray CJL, Roth GA. Global Burden of Cardiovascular Diseases and Risks, 1990-2022. J Am Coll Cardiol. 2023 Dec 19;82(25):2350–473.
Chooramani G, Samal J, Rani N, Singh G, Agarwal R, Bajpai M, et al. Performance evaluation of NeuMoDx 96 system for hepatitis B and C viral load. World J Virol. 2023 Sep 25;12(4):233–41.
